Women choosing weight-loss paths in 2026 select between Ozempic semaglutide, compounded GLP-1, or peptide therapy. Each works through different pathways and fits different clinical pictures.
Three Lanes for Womens Weight Loss 2026
Lane 1 Pharmaceutical GLP-1s Ozempic Wegovy Zepbound Mounjaro: 10-15 percent body weight loss over 12 months. Rebound 40-70 percent within 12 months of stopping. 25-40 percent muscle loss. Cost 900-1400/month brand or 200-500/month compounded. Best for BMI 30+.
Lane 2 Peptide Therapy: AOD-9604 lipolysis without growth hormone. Tesamorelin FDA-approved for lipodystrophy. CJC-1295 plus Ipamorelin preserve lean mass. BPC-157 supports gut integrity. Produces slower sustainable body-composition change.
Lane 3 Natural GLP-1 Stack: Acupuncture plus Chinese herbs plus hypnotherapy plus supplements. 60-80 percent of pharmaceutical results without rebound risk.
Ozempic vs Peptides
Speed: Ozempic fast 1-2 lb/week. Peptides slower but primarily fat. Rebound: Ozempic significant. Peptides minimal. Muscle: Ozempic loses lean mass. Peptides preserve or gain. Side effects women-specific: Ozempic nausea fatigue hair loss. Peptides injection-site reactions only. Cycle effects: Ozempic disrupts. Peptides generally not.
Framework for Choosing
Ozempic fits BMI 35+ with insulin resistance. Peptides fit BMI 27-33 with body composition goal and lean-mass preservation need. Natural stack fits BMI 25-30 wanting regulation restored.
Common Sequence
Six months Ozempic transition to CJC-1295/Ipamorelin for lean-mass recovery continue Natural GLP-1 Stack long-term. This is the Bright Post-GLP-1 Protocol approach.
Conclusion
Ozempic fastest results but rebounds hard. Peptides sustainable body-composition change without rebound. DAOM plus Functional Medicine framework selects based on insulin resistance lean-mass status perimenopausal context long-term goals with peptides always prescribed through collaborating MD or NP partner.